Brokerages expect that INSYS Therapeutics, Inc. (NASDAQ:INSY) will post earnings per share of ($0.15) for the current quarter, according to Zacks. Three analysts have made estimates for INSYS Therapeutics’ earnings, with estimates ranging from ($0.24) to ($0.10). INSYS Therapeutics posted earnings of $0.03 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 600%. The firm is scheduled to announce its next earnings results on Monday, April 2nd.
On average, analysts expect that INSYS Therapeutics will report full year earnings of ($0.39) per share for the current year, with EPS estimates ranging from ($0.46) to ($0.32). For the next fiscal year, analysts expect that the company will post earnings of ($0.43) per share, with EPS estimates ranging from ($0.73) to ($0.27). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow INSYS Therapeutics.
Several equities analysts have recently issued reports on INSY shares. Zacks Investment Research upgraded INSYS Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a research report on Tuesday, October 24th. Royal Bank Of Canada set a $8.00 price objective on INSYS Therapeutics and gave the company a “buy” rating in a report on Friday, October 27th. Jefferies Group LLC cut their target price on INSYS Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. TheStreet cut INSYS Therapeutics from a “c-” rating to a “d+” rating in a research note on Monday, August 21st. Finally, Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of INSYS Therapeutics in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. INSYS Therapeutics currently has an average rating of “Hold” and a consensus target price of $9.38.
Several hedge funds have recently bought and sold shares of INSY. Alliancebernstein L.P. increased its holdings in shares of INSYS Therapeutics by 128.6% during the 2nd quarter. Alliancebernstein L.P. now owns 140,840 shares of the specialty pharmaceutical company’s stock worth $1,782,000 after acquiring an additional 79,220 shares during the last quarter. Quantitative Investment Management LLC acquired a new position in shares of INSYS Therapeutics during the 2nd quarter worth approximately $879,000. Schneider Capital Management Corp increased its holdings in shares of INSYS Therapeutics by 100.0% during the 2nd quarter. Schneider Capital Management Corp now owns 119,973 shares of the specialty pharmaceutical company’s stock worth $1,518,000 after acquiring an additional 60,000 shares during the last quarter. Strs Ohio increased its holdings in shares of INSYS Therapeutics by 40.0% during the 2nd quarter. Strs Ohio now owns 175,000 shares of the specialty pharmaceutical company’s stock worth $2,213,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Marshall Wace North America L.P. acquired a new position in INSYS Therapeutics in the 2nd quarter valued at $612,000. 25.42% of the stock is currently owned by institutional investors and hedge funds.
INSYS Therapeutics (NASDAQ INSY) opened at $5.21 on Friday. INSYS Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.06.
COPYRIGHT VIOLATION WARNING: “INSYS Therapeutics, Inc. (INSY) Expected to Announce Earnings of -$0.15 Per Share” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://ledgergazette.com/2017/11/19/insys-therapeutics-inc-insy-expected-to-announce-earnings-of-0-15-per-share.html.
INSYS Therapeutics Company Profile
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INSYS Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INSYS Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.